Baidu
map

默克尔:欧盟对任何新冠疫苗都持开放态度

2021-02-03 张毅荣 任珂 新华网

德国总理默克尔2日表示,欧盟对任何新冠疫苗都持开放态度,欢迎任何疫苗企业向欧洲药品管理局提出申请。

德国总理默克尔2日表示,欧盟对任何新冠疫苗都持开放态度,欢迎任何疫苗企业向欧洲药品管理局提出申请。

默克尔当晚参加德国电视一台一档访谈节目时提到,塞尔维亚使用了中国新冠疫苗,接种速度更快。她紧接着表示:“我们衷心欢迎任何疫苗企业向欧洲药品管理局提出申请。”

默克尔还说,她已与俄罗斯总统谈论过相关问题,也看到了俄罗斯疫苗的良好数据,欧盟欢迎任何新冠疫苗,“不过只有疫苗企业向欧洲药品管理局提供必要数据,才可能获得批准”。

默克尔1日表示,如不出意外,即使仅有欧盟已批准的三款新冠疫苗供货,德国仍可实现“在今年夏季结束前向所有公民提供新冠疫苗”的目标,但若有其他疫苗获批,供应量将更大。

欧盟已批准使用的三款新冠疫苗分别由美国辉瑞制药公司与德国生物新技术公司、美国莫德纳公司、英国阿斯利康制药公司与牛津大学研发。默克尔1日介绍,美国强生公司以及德国“痊愈”疫苗公司研发的新冠疫苗也有望获批。

德国疾控机构罗伯特·科赫研究所公布的数据显示,截至2日0时,德国单日新增确诊病例6114例,累计确诊2228085例;新增死亡病例861例,累计死亡57981例。截至2日10时,德国新冠疫苗接种已超过258万剂。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1273957, encodeId=eea412e39571f, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Feb 05 12:45:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922652, encodeId=2529922652e3, content=厉害<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ec5456575, createdName=ms5000001852640370, createdTime=Thu Feb 04 00:50:12 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029075, encodeId=a8d610290e597, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Feb 04 00:45:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922647, encodeId=217c92264edd, content=天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200827/23619d3c1e944e23a9350a54edbacb81/d195c15802ae49df9886c39d3dcf868e.jpg, createdBy=e4295413629, createdName=ms3000000956234844, createdTime=Thu Feb 04 00:13:33 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1273957, encodeId=eea412e39571f, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Feb 05 12:45:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922652, encodeId=2529922652e3, content=厉害<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ec5456575, createdName=ms5000001852640370, createdTime=Thu Feb 04 00:50:12 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029075, encodeId=a8d610290e597, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Feb 04 00:45:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922647, encodeId=217c92264edd, content=天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200827/23619d3c1e944e23a9350a54edbacb81/d195c15802ae49df9886c39d3dcf868e.jpg, createdBy=e4295413629, createdName=ms3000000956234844, createdTime=Thu Feb 04 00:13:33 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1273957, encodeId=eea412e39571f, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Feb 05 12:45:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922652, encodeId=2529922652e3, content=厉害<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ec5456575, createdName=ms5000001852640370, createdTime=Thu Feb 04 00:50:12 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029075, encodeId=a8d610290e597, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Feb 04 00:45:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922647, encodeId=217c92264edd, content=天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200827/23619d3c1e944e23a9350a54edbacb81/d195c15802ae49df9886c39d3dcf868e.jpg, createdBy=e4295413629, createdName=ms3000000956234844, createdTime=Thu Feb 04 00:13:33 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-02-04 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1273957, encodeId=eea412e39571f, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Fri Feb 05 12:45:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922652, encodeId=2529922652e3, content=厉害<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ec5456575, createdName=ms5000001852640370, createdTime=Thu Feb 04 00:50:12 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029075, encodeId=a8d610290e597, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Feb 04 00:45:07 CST 2021, time=2021-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922647, encodeId=217c92264edd, content=天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200827/23619d3c1e944e23a9350a54edbacb81/d195c15802ae49df9886c39d3dcf868e.jpg, createdBy=e4295413629, createdName=ms3000000956234844, createdTime=Thu Feb 04 00:13:33 CST 2021, time=2021-02-04, status=1, ipAttribution=)]
    2021-02-04 ms3000000956234844

    天天向上

    0

相关资讯

欧盟批准Fintepla治疗Dravet综合征

Dravet综合征是一种罕见的儿童遗传性癫痫综合征,其特征是从婴儿期开始出现的难治性癫痫以及神经发育问题。70%-80%的DS患者检测出电压门控钠离子通道α-1亚基基因(SCN1A)突变。

被英国NICE拒绝后,强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣

欧盟委员会(EC)宣布扩大了强生的IL-23/IL-12靶向单抗Stelara(ustekinumab)的适应症,现在可用于治疗中度至重度斑块状牛皮癣的儿童患者(6-11岁)。

强生向欧盟申请将Spravato的适应症,扩展用于具有自杀倾向的抑郁症患者

强生宣布已向欧洲药品管理局(EMA)提交了其抑郁症(MDD)治疗药物Spravato(esketamine)的适应症扩展申请书。

辉瑞的美罗华仿制药RUXIENCE的营销申请,获得欧盟人用药物委员会的积极评价

辉瑞公司宣布,其美罗华(利妥昔单抗)的潜在的生物仿制药RUXIENCE的营销授权申请,获得欧洲药品管理局(EMA)的人用药品管理委员会(CHMP)的积极意见。

Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物,获得了CHMP的积极评价

Alnylam Pharmaceuticals的RNAi治疗药物Givlaari(givosiran),获得欧洲药品管理局的人用药品管理委员会(CHMP)的积极意见,用于治疗12岁以上的成人和青少年的急性肝卟啉症(AHP)。监管机构表示,如果Alnylam的申请得到批准,该靶向氨基乙酰丙酸合酶1的RNAi药物将成为欧盟中针对AHP的首个治疗药物。

艾伯维的JAK抑制剂Rinvoq,获得欧盟批准治疗类风湿性关节炎

艾伯维(AbbVie)宣布,欧洲委员会(EC)已批准其JAK抑制剂Rinvoq(upadacitinib)用于治疗部分中度至重度活动性类风湿关节炎患者。

Baidu
map
Baidu
map
Baidu
map